

Clinical Policy: Trifluridine/Tipiracil (Lonsurf)

Reference Number: CP.PHAR.383

Effective Date: 11.16.16

Last Review Date: 08.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Trifluridine/tipiracil (Lonsurf[®]) is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor.

FDA Approved Indication(s)

Lonsurf is indicated for the treatment of adult patients with:

- Metastatic colorectal cancer (CRC) as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy;
- Metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Lonsurf is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Colorectal Cancer (must meet all):**

1. Diagnosis of metastatic or advanced CRC;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Documentation of RAS (KRAS or NRAS) wild-type gene status;
5. Member has progressed through all available regimens for CRC that include all the following agents,* unless clinically significant adverse effects are experienced or all are contraindicated:
 - a. 5-fluorouracil or capecitabine;
 - b. Oxaliplatin and irinotecan;
 - c. An anti-VEGF agent: bevacizumab, Cyramza[®], Stivarga[®], or Zaltrap[®];
 - d. If tumor expresses the RAS wild-type gene, an anti-EGFR agent: Erbitux[®] or Vectibix[®];

**Prior authorization may be required.*

6. For brand Lonsurf requests, member must use generic trifluridine/tipiracil, if available, unless contraindicated or clinically significant adverse effects are experienced;
7. Prescribed as a single agent or in combination with bevacizumab*;
**Prior authorization may be required*
8. Documentation of member's body surface area (m²);
9. Request meets one of the following (a or b):*
 - a. Dose does not exceed 70 mg/m² per day up to a maximum of 160 mg per day (based on the trifluridine component; round dose to the nearest 5 mg increment given 15 and 20 mg tablets) on Days 1 through 5 and 8 through 12 of each 28-day cycle;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).
**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 12 months or duration of request, whichever is less

B. Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (must meet all):

1. Diagnosis of gastric cancer (GC) or GEJ adenocarcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. One of the following (a or b):
 - a. Disease is metastatic, advanced, unresectable, or recurrent;
 - b. Member is not a candidate for surgery;
5. Documentation of HER2/neu gene status;
6. Member has previously been treated with at least two prior lines of chemotherapy that include all of the following agents,* unless contraindicated or clinically significant adverse effects are experienced (a, b, and c):
 - a. 5-fluorouracil or capecitabine;
 - b. Cisplatin, carboplatin, or oxaliplatin;
 - c. Docetaxel, paclitaxel, or irinotecan;**Prior authorization may be required.*
7. If tumor is HER2/neu-positive (i.e., HER2-overexpressing): Failure of trastuzumab, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for trastuzumab.*
8. For brand Lonsurf requests, member must use generic trifluridine/tipiracil, if available, unless contraindicated or clinically significant adverse effects are experienced;
9. Prescribed as a single agent;
10. Documentation of member's body surface area (m²);
11. Request meets one of the following (a or b):*
 - a. Dose does not exceed 70 mg/m² per day up to a maximum of 160 mg per day (based on the trifluridine component; round dose to the nearest 5 mg increment given 15 and 20 mg tablets) on Days 1 through 5 and 8 through 12 of each 28-day cycle;

- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 12 months or duration of request, whichever is less

C. Appendiceal Cancer (off-label) (must meet all):

1. Diagnosis of one of the following appendiceal cancers (a, b, or c):
 - a. Appendiceal adenocarcinoma;
 - b. Undifferentiated carcinoma not otherwise specified;
 - c. Goblet cell adenocarcinoma;
2. Prescribed by or in consultation with an oncologist;
3. Age $\geq$ 18 years;
4. Member has progressed through all available regimens besides fruquintinib, regorafenib, or trifluridine/tipiracil with or without bevacizumab (see *Appendix B*);
5. Disease is recurrent, progressive, or extraperitoneal;
6. For brand Lonsurf requests, member must use generic trifluridine/tipiracil, if available, unless contraindicated or clinically significant adverse effects are experienced;
7. Prescribed as a single agent or in combination with bevacizumab*;
**Prior authorization may be required*
8. Documentation of member's body surface area (m^2);
9. Dose is within FDA maximum for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Medicaid/HIM/ICHRA – 12 months

Commercial – 12 months or duration of request, whichever is less

D. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/HIM) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Lonsurf for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. For brand Lonsurf requests, member must use generic trifluridine/tipiracil, if available, unless contraindicated or clinically significant adverse effects are experienced;
4. Documentation of member's body surface area (m²);
5. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 70 mg/m² per day up to a maximum of 160 mg per day (based on the trifluridine component) on Days 1 through 5 and 8 through 12 of each 28-day cycle;
 - b. New dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).*

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:

Medicaid/HIM/ICHRA – 12 months

Commercial – 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- ### A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

5-FU: 5-fluorouracil

CRC: colorectal carcinoma

EGFR: epidermal growth factor receptor

FDA: Food and Drug Administration

GC: gastric cancer

GEJ: gastroesophageal junction

VEGF: vascular endothelial growth factor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<i>Fluoropyrimidine, platinum, and irinotecan therapeutic agents and examples of regimens</i>		
5 FU (fluorouracil)*	CRC 400 mg/m² IV on day 1, 1,200 mg/m² for 2 days OR 225 mg/m² IV over 24 hours 5 to 7 days/week GC/GEJ adenocarcinoma 750-1,000 mg/m² IV daily on Days 2-4 of every 28-day cycle in combination with cisplatin OR 2,000 mg/m² IV on Day 1 of every 14-day cycle in combination with leucovorin and cisplatin OR 800 mg/m² IV on Days 1-5 of every 28-day cycle	2,400 mg/m ²
capecitabine (Xeloda [®])*	CRC 1,250 mg/m² PO BID on Days 1-14. Repeat every 21 days for 8 cycles. GC/GEJ adenocarcinoma 1000-1,250 mg/m² PO BID on Days 1-14 of every 21-day cycle OR 1,000 mg/m² PO BID on Days 1-14 in combination with cisplatin 80 mg/m² IV on Day 1 of every 21-day cycle OR	2500 mg/m ² /day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	1,000 mg/m ² PO BID on Days 1-14 in combination with oxaliplatin 130 mg/m ² IV on Day 1 of every 21-day cycle	
irinotecan (Camptosar [®])	CRC 125 mg/m² IV in combination with 5-FU based chemotherapy GC/GEJ adenocarcinoma 180 mg/m² IV on Day 1 of each 14-day cycle in combination with leucovorin and fluorouracil OR 80 mg/m² IV on Day 1 weekly for 6 weeks followed by 2 weeks off treatment, in combination with leucovorin and fluorouracil	350 mg/m ²
oxaliplatin	85 mg/m ² IV in combination with 5-FU based chemotherapy	130 mg/m ²
FOLFOX = Infusional 5-FU/leucovorin /Eloxatin [™] (oxaliplatin)	CRC Eloxatin (oxaliplatin) 85 mg/m² IV on Day 1; leucovorin 200 mg/m² IV on Days 1 & 2, followed by 5-FU 400 mg/m² IV bolus, followed by 5-FU 600 mg/m² IV on Days 1 & 2. Repeat cycle every 14 days. Gastric cancer/GEJ adenocarcinoma Eloxatin (oxaliplatin) 85 mg/m² IV on Day 1; leucovorin 400 mg/m² IV on Day 1; 5-FU 400 mg/m² IV bolus on Day 1, followed by 5-FU 1,200 mg/m² IV on Days 1 & 2. Repeat cycle every 14 days. OR Eloxatin (oxaliplatin) 85 mg/m² IV on Day 1; leucovorin 200 mg/m² IV on Day 1; 5-FU 2,600 mg/m² IV continuous infusion on Day 1. Repeat cycle every 14 days.	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
FOLFIRI = Infusional 5-FU/leucovorin/ irinotecan (Camptosar [®])	CRC Irinotecan 180 mg/m² IV over 90 minutes day 1; leucovorin 400 mg/m² IV over 2 hours day 1 followed by 5-FU 400 mg/m² IV bolus over 2-4 minutes, followed by 2.4-3 gm/m² IV 5-FU continuous infusion over 46 hours. Repeat cycle every 14 days. GC/GEJ adenocarcinoma Irinotecan 180 mg/m² IV on Day 1; leucovorin 400 mg/m² IV on Day 1; 5-FU 400 mg/m² IV bolus on Day 1, followed by 1200 mg/m² IV continuous infusion on Days 1 and 2. Repeat cycle every 14 days.	Varies
Anti-VEGF therapy for CRC		
Avastin, Mvasi, Zirabev (bevacizumab, bevacizumab-awwb, bevacizumab-bvzr)	5 or 10 mg/kg IV every 14 days in combination with 5-FU based chemotherapy	20 mg/kg
Cyramza (ramucirumab)	8 mg/kg IV every 2 weeks plus FOLFIRI regimen	10 mg/kg per dose
Stivarga (regorafenib)	160 mg PO QD on Days 1-21 of each 28-day cycle	160 mg/day
Zaltrap (ziv-aflibercept)	4 mg/kg IV every 14 days in combination with FOLFIRI	4 mg/kg every 2 weeks
Anti-EGFR therapy for CRC		
Erbitux (cetuximab)	400 mg/m ² IV for initial dose, then weekly infusions of 250 mg/m ² IV	400 mg/m ²
Vectibix (panitumumab)	6 mg/kg IV every 2 weeks	9 mg/kg every 3 weeks
HER2/neu therapy for GC or GEJ adenocarcinoma		
Herceptin, Hercessi, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera (trastuzumab, trastuzumab- pkrb,anns,dttb,dkst,qyyp)	With chemotherapy: 8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days OR 6 mg/kg IV loading dose on Day 1 of cycle 1, then 4 mg/kg IV every 14 days	8 mg/kg/dose

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<i>Taxanes for GC or GEJ adenocarcinoma</i>		
docetaxel	75-100 mg/m ² IV on Day 1 of every 21-day cycle	100 mg/m ²
paclitaxel	135-250 mg/m ² IV on Day 1 of every 21-day cycle OR 80 mg/m ² IV on Day 1 weekly of every 28-day cycle OR 80 mg/m ² IV on Days 1, 8, and 15 of every 28-day cycle	250 mg/m ²
<i>Appendiceal Cancer: Examples of Available Therapies</i>		
<u>Initial therapies:</u> • CAPEOX ± bevacizumab • FOLFIRI ± bevacizumab • FOLFIRINOX ± bevacizumab • FOLFOX ± bevacizumab • capecitabine ± bevacizumab fluorouracil/leucovorin ± bevacizumab	Varies	Varies
<u>Second-line and subsequent therapies:</u> • (FOLFIRI or irinotecan) ± bevacizumab • FOLFIRINOX ± bevacizumab • (CAPEOX or FOLFOX) ± bevacizumab • IROX ± bevacizumab Biomarker-directed therapies: encorafenib, cetuximab, panitumumab, adagrasib, sotorasib, pertuzumab, tucatinib, trastuzumab, fam-trastuzumab deruxtecan-nxki, entrectinib, larotrectinib, repotrectinib, selpercatinib	Varies	Varies
<u>For any line of therapy (if dMMR/MSI-H or</u>	Varies	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
<u>POLE/POLD1 mutation</u>): cemiplimab-rwlc, dostarlimab-gxly, ipilumab, nivolumab, pembrolizumab, penpulimab-kcqx, retifanlimab-dlwr, tislelizumab-jsgr, toripalimab-tpzi		

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

**5-FU and capecitabine are examples of fluoropyrimidine chemotherapeutic agents.*

† FOLFOX: oxaliplatin, leucovorin, fluorouracil (5-FU); CAPEOX: oxaliplatin, capecitabine (Xeloda); FOLFIRI: irinotecan, leucovorin, 5-FU; FOLFOXIRI: irinotecan, oxaliplatin, leucovorin, 5-FU; IROX: oxaliplatin, irinotecan

Appendix C: Contraindications/Boxed Warnings

None reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Metastatic CRC, GC, and GEJ adenocarcinoma	35 mg/m ² /dose PO BID on Days 1 through 5 and Days 8 through 12 of each 28-day cycle	160 mg/day (based on the trifluridine component)

VI. Product Availability

Tablets: 15 mg trifluridine/6.14 mg tipiracil, 20 mg trifluridine/8.19 mg tipiracil

VII. References

1. Lonsurf Prescribing Information. Princeton, NJ: Taiho Oncology; August 2023. Available at: www.lonsurfhcp.com. Accessed April 13, 2026.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. May 16, 2026.
3. National Comprehensive Cancer Network. Colon Cancer Version 2.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Accessed May 16, 2026.
4. National Comprehensive Cancer Network. Rectal Cancer Version 2.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Accessed May 16, 2026.
5. National Comprehensive Cancer Network. Gastric Cancer Version 2.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed May 16, 2026.
6. National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers Version 2.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. Accessed May 16, 2026.
7. Micromedex[®] Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed May 16, 2026.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Template changes applied to other diagnoses/indications.	09.22.22	
3Q 2023 annual review: no significant changes; references reviewed and updated.	04.20.23	08.23
RT4: added new FDA indication for mCRC in combination with bevacizumab to FDA-approved indications section.	08.15.23	
3Q 2024 annual review: no significant changes; references reviewed and updated.	05.06.24	08.24
3Q 2025 annual review: no significant changes; references reviewed and updated.	04.24.25	08.25
3Q 2026 annual review: added ICHRA line of business; for appendiceal carcinoma, moved out of CRC criteria to its own criteria set to reflect additional disease-specific recommendations for use; revised initial approval duration from 6 months to 12 months for Medicaid, HIM, and ICHRA line of business; references reviewed and updated.	04.13.26	08.26

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan

retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.